CytomX Therapeutics (CTMX) Profit After Tax (2014 - 2026)

CytomX Therapeutics (CTMX) has 13 years of Profit After Tax data on file, last reported at -$18.3 million in Q1 2026.

• Quarterly Profit After Tax fell 177.7% year-over-year to -$18.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$59.2 million (down 242.12% YoY) and the FY2025 annual result came in at -$17.4 million, down 154.5% from the prior year.
• Profit After Tax advanced to -$18.3 million in Q1 2026, from -$26.5 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $23.5 million in Q1 2025 to a low of -$32.0 million in Q1 2022.
• A 5-year average of -$6.1 million and a median of -$3.3 million in 2023 frame the typical range for Profit After Tax.
• The widest YoY moves for Profit After Tax: up 2155.2% in 2024, down 501.1% in 2024.
• Tracing CTMX's Profit After Tax over 5 years: stood at -$8.8 million in 2022, then soared by 109.54% to $837000.0 in 2023, then jumped by 2155.2% to $18.9 million in 2024, then tumbled by 240.44% to -$26.5 million in 2025, then jumped by 31.13% to -$18.3 million in 2026.
• The last three Profit After Tax figures came in at -$18.3 million (Q1 2026), -$26.5 million (Q4 2025), and -$14.2 million (Q3 2025), per Business Quant data.